SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

NKTX

Nkarta, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The EPS miss is minor and offset by improved cash position and regulatory progress. The key catalyst is initial clinical data expected in 2026, monitor for presentation date. No immediate trading trigger; stock likely range-bound until data readout.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$3.06
T+0 close · May 12, 2026 · via day close
Latest settled
−9.80%
T+20 · $2.76
Vs SPY
−9.19%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 13 $3.06entry
  2. T+1 · 6mo ago 0.00%α +0.00% · $3.06
  3. T+5 · 6mo ago −12.42%α −11.26% · $2.68
  4. T+20 · 5mo ago −9.80%α −9.19% · $2.76
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The company highlighted FDA agreement for outpatient dosing and expansion into rheumatoid arthritis, with initial clinical data expected in 2026. Cash runway into 2029 provides stability, but the EPS miss and lack of near-term catalysts keep sentiment neutral.

Key Financial Metrics

EPS
−$0.37
est −$0.36 · -2.8%
Rating
miss

Key Facts

  • Q1 2026 EPS: -$0.37 vs consensus -$0.36 (miss of 2.8%)
  • No revenue reported (pre-revenue biotech)
  • Cash balance: $266.7M as of March 31, 2026, expected to fund operations into 2029
  • Net loss: $27.8M for Q1 2026, improved from $32.0M in Q1 2025
  • FDA agreement to allow outpatient dosing, re-dosing, and expansion into rheumatoid arthritis
  • Initial clinical data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026

Financial Impact

EPS miss of $0.01 vs consensus; net loss improved by $4.2M YoY; cash burn of ~$28.4M in Q1

epscashnet loss

Risk Factors

  • Clinical trial failure or disappointing data
  • Dilution risk if cash runway shortens
  • Regulatory setbacks despite recent FDA agreement

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293350

Track record

13 reports on NKTX

Performance horizon

5 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +31.21% at T+5 after the Nov 5, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  2. Nov 9, 20267d ago Press Release Bullish 7/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  3. Nov 6, 202610d ago 8-K Neutral 3/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
  6. Aug 10, 202614w ago 8-K Bearish 6/10 Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
  7. May 12, 202626w ago Press Release Neutral 4/10 Viewing Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
  8. Apr 15, 202630w ago Press Release Bullish 7/10 Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
  9. Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
  10. Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026